Hervé Duchesne de Lamotte
Director/Board Member at EUROBIO SCIENTIFIC
Net worth: 750 988 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Denis Fortier | M | - |
Eurobio Ingen SA
 Eurobio Ingen SA Medical SpecialtiesHealth Technology Eurobio Ingen SA develops, manufactures, and markets reagents for research and biomedical diagnosis. The private company is based in Rungis, France. Jean-Michel Carle has been the CEO of the French company since 2017.
Eurobio SAS
 Eurobio SAS Pharmaceuticals: MajorHealth Technology Eurobio SAS develops and distributes reagents for research as well for biomedical diagnosis. It works closely with scientists in research institutes including CNRS, INSERM, INRA, CNEVA, alongside life science companies, universities, hospitals and medical laboratories. The firm has two operating divisions: Life Sciences and Diagnostics managed by high-performing staff. The company was founded by Stephane Réveilleau on 1962 and is headquartered in Courtaboeuf, France.
Capforce Plus SAS
 Capforce Plus SAS Medical SpecialtiesHealth Technology Capforce Plus SAS is a French company that manufactures IVD equipment. The private company is based in Les Ulis, France. Denis Fortier has been the CEO of the company since 2014. | 10 years |
| Jean-Michel Carle | M | - |
Eurobio Ingen SA
Eurobio Ingen SA Medical SpecialtiesHealth Technology Eurobio Ingen SA develops, manufactures, and markets reagents for research and biomedical diagnosis. The private company is based in Rungis, France. Jean-Michel Carle has been the CEO of the French company since 2017.
Eurobio SAS
Eurobio SAS Pharmaceuticals: MajorHealth Technology Eurobio SAS develops and distributes reagents for research as well for biomedical diagnosis. It works closely with scientists in research institutes including CNRS, INSERM, INRA, CNEVA, alongside life science companies, universities, hospitals and medical laboratories. The firm has two operating divisions: Life Sciences and Diagnostics managed by high-performing staff. The company was founded by Stephane Réveilleau on 1962 and is headquartered in Courtaboeuf, France. | 7 years |
| Michel Picot | M | 72 |
Exonhit
 Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 20 years |
| James Hicks | M | 77 |
GenDx, Inc.
 GenDx, Inc. Medical/Nursing ServicesHealth Services GenDx, Inc. provides healthcare services. The private company is based in New York, NY. | - |
| Anne-Sophie Herelle | F | 43 | 2 years | |
| Steven J. Winick | M | - |
GenDx, Inc.
GenDx, Inc. Medical/Nursing ServicesHealth Services GenDx, Inc. provides healthcare services. The private company is based in New York, NY. | - |
| Patrick de Roquemaurel | M | 67 | 7 years | |
| Cathie Marsais | F | - | - | |
| Thomas Moreaux | M | - | - | |
| Eric Pryjda | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Laurent Condomine | M | 79 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 13 years |
| Patrick J. Langlois | M | 78 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 2 years |
| Jean-Pierre Hermet | M | 80 |
InGen Biosciences SA
 InGen Biosciences SA Medical SpecialtiesHealth Technology InGen Biosciences SA is engaged in the development of in-vitro diagnostic products for use in medical biology laboratories. The company was founded in 1993 and it is headquartered in Chilly-Mazarin, France. | 3 years |
| Loïc Maurel | M | 69 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 4 years |
| Matthew P. Pando | M | 52 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 4 years |
| Deborah A. Smeltzer | F | 70 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | - |
| Christophe Jean | M | 67 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | - |
| Jean-Jacques de Jaegher | M | - | - | |
| Laurent Bracco | M | - |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | - |
| Corinne Hoff | F | - |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | - |
| Frédéric Joël Desdouits | M | 57 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 3 years |
| Isabelle Barber | M | 55 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 2 years |
| Danièle Guyot-Caparros | F | 64 | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| France | 21 | 91.30% |
| United States | 2 | 8.70% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Hervé Duchesne de Lamotte
- Personal Network
